A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Drug: SHR-A1811 administered intravenously every 3 weeks (Q3W)

"Drug: Camrelizumab administered intravenously every 3 weeks (Q3W)~Drug: Pemetrexed Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Paclitaxel Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Carboplatin Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Cisplatin Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)"